Tandem Diabetes Care (Tandem Diabetes Care) Cash-to-Debt : 0.98 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Tandem Diabetes Care Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tandem Diabetes Care's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.98.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Tandem Diabetes Care couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Tandem Diabetes Care's Cash-to-Debt or its related term are showing as below:

TNDM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17 Med: 1.67 Max: No Debt
Current: 0.98

During the past 13 years, Tandem Diabetes Care's highest Cash to Debt Ratio was No Debt. The lowest was 0.17. And the median was 1.67.

TNDM's Cash-to-Debt is ranked worse than
62.14% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: 1.91 vs TNDM: 0.98

Tandem Diabetes Care Cash-to-Debt Historical Data

The historical data trend for Tandem Diabetes Care's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tandem Diabetes Care Cash-to-Debt Chart

Tandem Diabetes Care Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

8.66

2.12

1.98

1.47

1.13

Tandem Diabetes Care Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															1.24	1.21	1.19	1.13	0.98

Competitive Comparison of Tandem Diabetes Care's Cash-to-Debt

For the Medical Devices subindustry, Tandem Diabetes Care's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tandem Diabetes Care's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's Cash-to-Debt falls into.

Tandem Diabetes Care Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Tandem Diabetes Care's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	467.912	/	(17.06	+	398.607)
	=	1.13

Tandem Diabetes Care's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	467.81	/	(17.32	+	460.229)
	=	0.98

Tandem Diabetes Care (NAS:TNDM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Tandem Diabetes Care Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Tandem Diabetes Care's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Tandem Diabetes Care (Tandem Diabetes Care) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (NAS:TNDM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

TD5A:Germany

Address

11075 Roselle Street, San Diego, CA, USA, 92121

Website

https://www.tandemdiabetes.com

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Executives

Dick Allen	director	11045 ROSELLE STREET, SAN DIEGO CA 92121
Shannon Marie Hansen	officer: SVP & General Counsel	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Leigh Vosseller	officer: Senior Vice President and CFO	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kathleen Mcgroddy-goetz	director	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Peyton R Howell	director	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
David B Berger	officer: GENERAL COUNSEL	11045 ROSELLE STREET, SAN DIEGO CA 92121
Malagueira Joao Paulo Falcao	director	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Myoungil Cha	director	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kim D Blickenstaff	director, officer: PRESIDENT AND CEO	C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
John F Sheridan	officer: EXECUTIVE VP AND COO	C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
Christopher J Twomey	director	4767 NEXUS CENTRE DRIVE, SAN DIEGO CA 92121
Rebecca B Robertson	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
James Leal	officer: SVP, Operations	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Elizabeth Anne Gasser	officer: EVP, Chief Strategy Officer	C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Susan Morrison	officer: CAO	11045 ROSELLE STREET, SAN DIEGO CA 92121